Regeneron Pharmaceuticals
REGN
920.69
-1.71
-0.19%
Regeneron Pharmaceuticals
US · REGN
#285 by market cap
Listed 1970
920.69
-1.71
-0.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Leerink Partners Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Announces Target Price $835Market Newswire · 2026/10/20
-
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,050Market Newswire · 2026/11/19
-
Rating change
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $865Market Newswire · 2026/10/19
-
Form 144 | Regeneron Pharmaceuticals(REGN.US) Officer Proposes to Sell 4.77 Million in Common StocksMarket Newswire · 2026/11/18
-
Rating change
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $920Market Newswire · 2026/10/12
-
Rating change
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $982 to $1,175Market Newswire · 2026/11/3
-
Company notice
LYC Healthcare: MEXTER TECHNOLOGY BERHAD (MEXTER) • PROPOSED ACQUISITION BY ITS 80% OWNED SUBSIDIARY MEXCOMM SDN BHD (777810-D) OF A 49% EQUITY INTEREST IN E-G6 SOLUTION (THAILAND) CO. LTD. (REGN NO. 0105551096920) (“THE COMPANYâ€) (“ACQUISITIONâ€Bursa Malaysia · 2012/8/6
-
Rating change
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,030Market Newswire · 2026/11/11
-
Rating change
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,050Market Newswire · 2026/11/4
-
Rating change
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $922Market Newswire · 2026/10/28
-
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,075Market Newswire · 2026/11/17
-
Rating change
Scotiabank Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $770Market Newswire · 2026/10/14
-
Rating change
UBS Initiates Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $978Market Newswire · 2026/10/15
-
Rating change
UBS Group: Resumes coverage of Regeneron Pharmaceuticals (REGN.US) with a "Buy" rating; blockbuster drug Dupixent's potential is undervaluedZhitong Finance · 2026/10/15
-
Rating change
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $980Market Newswire · 2026/10/21
-
Rating change
UBS Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $978Market Newswire · 2026/10/16
-
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,175Market Newswire · 2026/11/12
-
Rating change
Leerink Partners Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $835Market Newswire · 2026/10/21
-
Rating change
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $825 to $1,050Market Newswire · 2026/10/31
-
Regeneron Pharmaceuticals(REGN.US) Officer Sells US$4.8 Million in Common StockMarket Newswire · 2026/11/19
-
Rating change
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $908Market Newswire · 2026/10/12
-
Regeneron Pharmaceuticals(REGN.US) Officer Sells US$4.31 Million in Common StockMarket Newswire · 2026/11/5
-
Regeneron Pharmaceuticals(REGN.US) Director Sells US$20.38 Million in Common StockMarket Newswire · 2026/11/5
-
Regeneron Pharmaceuticals(REGN.US) Director Sells US$7.59 Million in Common StockMarket Newswire · 2026/11/5
-
Regeneron Pharmaceuticals(REGN.US) Officer Sells US$3.83 Million in Common StockMarket Newswire · 2026/11/7
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Regeneron Pharmaceuticals discussion 0 comments